



HAL
open science

G-CSF protects motoneurons against axotomy-induced apoptotic death in neonatal mice.

Alexandre Henriques, Claudia Pitzer, Luc Dupuis, Armin Schneider

► **To cite this version:**

Alexandre Henriques, Claudia Pitzer, Luc Dupuis, Armin Schneider. G-CSF protects motoneurons against axotomy-induced apoptotic death in neonatal mice.. *BMC Neuroscience*, 2010, 11 (1), pp.25. 10.1186/1471-2202-11-25 . inserm-00663774

HAL Id: inserm-00663774

<https://inserm.hal.science/inserm-00663774v1>

Submitted on 27 Jan 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESEARCH ARTICLE

Open Access

G-CSF protects motoneurons against axotomy-induced apoptotic death in neonatal mice

Alexandre Henriques^{1,2,3}, Claudia Pitzer^{1*}, Luc Dupuis^{2,3}, Armin Schneider^{1*}

Abstract

Background: Granulocyte colony stimulating factor (G-CSF) is a growth factor essential for generation of neutrophilic granulocytes. Apart from this hematopoietic function, we have recently uncovered potent neuroprotective and regenerative properties of G-CSF in the central nervous system (CNS). The G-CSF receptor and G-CSF itself are expressed in α motoneurons, G-CSF protects motoneurons, and improves outcome in the SOD1(G93A) transgenic mouse model for amyotrophic lateral sclerosis (ALS). In vitro, G-CSF acts anti-apoptotically on motoneuronal cells. Due to the pleiotrophic effects of G-CSF and the complexity of the SOD1 transgenic ALS models it was however not possible to clearly distinguish between directly mediated anti-apoptotic and indirectly protective effects on motoneurons. Here we studied whether G-CSF is able to protect motoneurons from purely apoptotic cell death induced by a monocausal paradigm, neonatal sciatic nerve axotomy.

Results: We performed sciatic nerve axotomy in neonatal mice overexpressing G-CSF in the CNS and found that G-CSF transgenic mice displayed significantly higher numbers of surviving lumbar motoneurons 4 days following axotomy than their littermate controls. Also, surviving motoneurons in G-CSF overexpressing animals were larger, suggesting additional trophic effects of this growth factor.

Conclusions: In this model of pure apoptotic cell death the protective effects of G-CSF indicate direct actions of G-CSF on motoneurons in vivo. This shows that G-CSF exerts potent anti-apoptotic activities towards motoneurons in vivo and suggests that the protection offered by G-CSF in ALS mouse models is due to its direct neuroprotective activity.

Background

Granulocyte-colony-stimulating factor is a cytokine that stimulates the proliferation and the differentiation of myeloid precursors [1] and has been in clinical use for more than 10 years in indications related to counteracting chemotherapy-induced neutropenia or for bone-marrow transplantations [2]. We and others discovered that G-CSF also acts as a growth factor in the brain, and shows protective and regenerative properties in a number of CNS disease models [3-6]. The mechanisms leading to these beneficial effects likely include a combination of anti-apoptotic activity on neurons [5], stimulation of neurogenesis [5], enhancement of vessel formation [3], mobilization of bone marrow derived cells [4] and systemic anti-inflammatory effects [5]. Recently we described that G-CSF was

protective in a mouse model of amyotrophic lateral sclerosis (ALS), the major adult-onset motoneuron disease. G-CSF treatment increased survival and volume of spinal α motoneurons and protected motoneuronal cell lines (NSC34) in vitro against apoptotic stimuli [6]. Importantly, while adult motoneurons prominently express the receptor for G-CSF [6,7] our studies did not unequivocally show that G-CSF exerted protection in this ALS model through its neuroprotective activity.

Here, we sought to determine whether G-CSF was able to protect motoneurons in vivo in a model of neonatal sciatic nerve axotomy. This experimental paradigm has been largely described, is thought to rely almost exclusively on the apoptotic machinery [8], and provides a powerful tool to study the neuroprotective activity of growth factors towards motoneurons in vivo [4,5,9-13].

* Correspondence: Pitzer@Sygnis.de; Schneider@Sygnis.de
¹SYGNIS Bioscience, Im Neuenheimer Feld 515, 69120 Heidelberg, Germany

Results

The G-CSF receptor is expressed on neonatal motoneurons, and induced by axotomy

We have previously shown that the receptor of G-CSF (G-CSFR) is expressed on motoneurons in the adult spinal cord. We first determined whether the G-CSF receptor was expressed on motoneurons during early postnatal development. At postnatal day 9 (P9) we noted expression of the receptor on α motoneurons in the spinal cord ventral horn, identified by the following criteria: Choline-Acetyltransferase (CHAT) expression, an identifiable nucleolus, and a size larger than $300 \mu\text{m}^2$ in the horizontal dimension (Figure 1). Invariably, all motoneurons defined by these criteria expressed the receptor.

The expression of G-CSF receptor is induced by neurons under neurodegenerative conditions such as after cerebral ischemia or in ALS, presumably as an endogenous protective response [6,7]. We therefore examined expression of the G-CSF receptor by quantitative PCR of whole spinal cords 4 days following neonatal axotomy of the right sciatic nerve (i.e. on postnatal day 9). Indeed, we found that G-CSFR expression in the whole spinal cord increased by 55% ($p < 0.005$) (Figure 2A).


To clarify whether this induction likely originated from the injured motoneurons, we quantified fluorescent staining intensities of ipsi- and contralateral motoneurons from the lumbar spinal cord region. We detected significantly stronger protein expression on ipsi- versus contralateral motoneurons, suggesting that axotomized motoneurons upregulate the receptor in response to injury ($p < 0,05$) (Figure 2B).

In conclusion, the G-CSF receptor is expressed at the neonatal stage and its expression is increased in response to axotomy.


CNS- targeted overexpression of G-CSF protects motoneurons against cell death in neonatal pups

Neonatal motoneuron death following sciatic nerve axotomy constitutes a widely used and well- established model of apoptotic motoneuron death that has been used to examine protective effects of trophic factors.


We chose to use transgenic mice that overexpress G-CSF in the CNS as an endogenous "delivery system" to study effects of increased concentration of G-CSF on the lesioned motoneurons. We used transgenic mice harbouring a bidirectional tta-responsive construct with expression cassettes for murine G-CSF and EYFP (pBEG). These mice were crossed with mice expressing the Tet-transactivator under control of the CaMKII α -promoter, similar to the approach used in Pitzer et al. except for the use of the Thy1-driver used therein [7]. In the following we compare three types of transgene



combinations in littermates derived from crosses of mice heterozygous for the transgene CaMKII-tTA and heterozygous for pBEG. The three groups are a.) mice not harbouring any transgene ("wt"), b.) mice harbouring only the BEG2 transgene (which do not express G-CSF), and c.) mice harbouring both the BEG2 transgene and the CaMKII-tTA driver, that do express G-CSF.



Although expression via the CaMKII driver in our transgenes is mainly in the forebrain, release of G-CSF in the spinal cord is expected from long corticospinal axonal connections. Indeed, the CaMKII α -promoter directed G-CSF overexpression in the forebrain leads to a strong elevation of G-CSF levels in the neonatal brain and spinal cord (P9; 28.00 \pm 11.60 vs 0.24 \pm 0.23 pg/mg tissue protein; p < 0.05) (Figure 3).



Offspring from crosses of BEG and CaMK-tta transgenic mice were subjected to complete unilateral sciatic nerve axotomy at postnatal day 5 (P5). We analyzed effects on motoneuron survival in the lumbar section of the spinal cord (L4/5 levels) after 4 days at P9. Examples of the histological appearance of CHAT positive cells in the ventral horn of the lumbar spinal cord of neonatal mice after sciatic nerve axotomy are given in figure 4. Our axotomy model results in a loss of approximately 40 - 50% of motoneurons 4 days after the injury (Figure 4A and 4B; Figure 5A and 5B), a result consistent with other studies [8,9]. Already apparent from the histological sections was that clearly more motoneurons survive in mice with the G-CSF transgene activated by the CaMK-tta driver (BEG -/T CaMK -/T) (compare figure 4B and 4F).

We then quantified numbers of motoneurons in the lumbar spinal cord of P9 neonatal mice contra- and ipsilateral to the side of axotomy. The α motoneurons were defined as (i) being situated in the ventral horn of the lumbar region; (ii) having a clearly identifiable nucleolus and staining positive for CHAT and (iii) having a minimum cross-sectional area of 300 μ m².

There was no difference between the absolute numbers of motoneurons on the contralateral side between the three genotypes used, although there was a non-significant trend for slightly higher numbers in the double-transgenic group (BEG -/T CaMK -/T (7.03 \pm 0.39 motoneurons/section) vs. BEG -/T CaMK -/- (5.98 \pm 0.38) and





Figure 4 Examples of the histological evaluation of CHAT positive cells in the ventral horn of the lumbar spinal cord of neonatal mice after sciatic nerve axotomy. Sections from the lumbar spinal cord were stained with CHAT antibodies. (A, B) Examples of motoneurons in the ventral horn contralateral and ipsilateral to the lesion side in BEG $-/-$ CaMK $-/-$ mice (wild type littermates). (C, D) Examples of lumbar sections contra- and ipsilateral to the lesion from a BEG $-/T$ CaMK $-/-$ littermate (non-G-CSF expressing). (E, F) Examples of lumbar sections contra- and ipsilateral to the lesion from a G-CSF overexpressor (BEG $-/T$ CaMK $-/T$ mouse). (B, D, F) There are more CHAT-positive cells detectable 4 days after axotomy on the ipsilateral side in mice overexpressing G-CSF (BEG $-/T$ CaMK $-/T$). All photomicrographs with 20x original magnification (OM), size bar 50 μ m.

wt (6.1 ± 0.28); $p = 0.1$ by ANOVA) (Figure 5A). On the axotomized side, sciatic nerve axotomy dramatically decreased the numbers of motoneurons in animals lacking the CaMK-tta driver transgene, whereas double transgenic animals showed significantly higher numbers of surviving motoneurons (BEG $-/T$ CaMK $-/T$: 5.43 ± 0.28 motoneurons/section; BEG $-/T$ CaMK $-/-$: 3.79 ± 0.27 and wt: 3.15 ± 0.20 ; $p < 0.0001$ by ANOVA and Fisher's LSD post-hoc analysis) (Figure 5B). We also directly compared the fraction of surviving motoneurons relative to the unlesioned side (Figure 5C). This analysis revealed that only 50 - 60% of the motoneurons

survived in the genotypes lacking the CaMK-tta driver transgene, whereas close to 90% of the motoneurons survived in the double transgenic mice (i.e. in animals overexpressing G-CSF) (BEG $-/T$ CaMK $-/T$ ($88.76 \pm 4.32\%$) vs. BEG $-/T$ CaMK $-/-$ ($62.14 \pm 4.22\%$) and wt ($51.93 \pm 3.02\%$); $p < 0.0001$ by ANOVA and Fisher's LSD post-hoc analysis).


G-CSF preserves motoneuron size after axotomy

Our previous results in ALS mice had shown that the shrinking of motoneurons in the SOD1(G93A) transgenic mice was partially restored by G-CSF treatment.



To determine whether this was also the case after sciatic nerve axotomy, we studied the distribution of motoneuron size of all motoneurons including those that are $< 300 \mu\text{m}^2$ determined by their cross-sectional area in the horizontal plane in all cells that were situated in the ventral horn, had a nucleolus, and were CHAT-positive. On the contralateral side, size distribution was similar between the three genotypes (Figure 6, hatched bars; BEG $-/T$ CaMK $-/T$ ($442.55 \pm 11.08 \mu\text{m}^2$); BEG $-/T$ CaMK $-/-$ ($431.84 \pm 12.52 \mu\text{m}^2$); wt ($434.20 \pm 9.74 \mu\text{m}^2$); $p = 0.78$ by ANOVA).

On the ipsilateral (axotomized) side, there was a downward shift in the mean size of the motoneurons in the littermates that did not overexpress G-CSF (wt and BEG $-/T$ CaMK $-/-$). On the contrary, double transgenic animals (BEG $-/T$ CaMK $-/T$) displayed a relatively preserved motoneuron size, suggesting a healthier state of those cells (Figure 6, solid bars; BEG $-/T$ CaMK $-/T$ ($464 \pm 17 \mu\text{m}^2$); BEG $-/T$ CaMK $-/-$ ($391 \pm 12 \mu\text{m}^2$); wt ($353 \pm 13 \mu\text{m}^2$); $p < 0.001$; ANOVA followed by Fisher's LSD). This result was also obtained if we only consider the α motoneurons that were counted for determining cell survival ($> 300 \mu\text{m}^2$): $555.85 \pm 17.43 \mu\text{m}^2$ (BEG $-/T$



CaMK $-/-$); $484.32 \pm 19.73 \mu\text{m}^2$ (BEG $-/-$ CaMK $-/-$); $477.68 \pm 17.93 \mu\text{m}^2$ (wt); $p = 0.0029$ by ANOVA. Additional file 1 shows a histogram distribution of motoneurons contra- and ipsilateral to the axotomy. A detailed summary of all data measured is given in additional file 2.

Discussion

Here we show that the receptor for G-CSF is expressed by neonatal motoneurons and that G-CSF protects lumbar motoneurons in a model of neonatal sciatic nerve axotomy. We have chosen this model because of the clarity of the involved pathophysiology to obtain more insight into the nature of G-CSF's effect on motoneurons. Sendtner et al. first described rescue of motoneuron death caused by neonatal axotomy by the growth factor CNTF [12]. This was followed by demonstration of a number of other neurotrophic factors protective in this paradigm. A series of papers then defined this axotomy-induced motoneuron death as apoptosis, with involvement of bcl proteins, AKT, IAPs, and caspases [14-16]. Overexpression of G-CSF protects lumbar motoneurons to an extent that is comparable to many of the classic neurotrophic factors. The experiments done here are therefore a further step in redefining G-CSF as a neurotrophic factor.

On top of a relative increase of motoneuron numbers following overexpression of G-CSF, we also noted an increase of about $100 \mu\text{m}^2$ in the mean cross-sectional area of surviving motoneurons. This suggests a functionally more active, or healthier state of those motoneurons. This has also been noted in adult SOD1(G93A) mice by us previously [7]. This finding might point to an additional trophic effect of G-CSF in addition to counteracting apoptosis. Alternatively, this could signify a proportionally greater anti-apoptotic effect size of G-CSF on larger motoneurons which potentially express more receptors on the cell surface.

We have studied motoneuron survival 4 days after axotomy with the aim to demonstrate that G-CSF can counteract apoptosis in motoneurons *in vivo* in a simple paradigm as a mean to better dissect mechanisms of action in the more complex ALS mouse models. We do not know how transient this effect may be, and whether increased survival would still be detectable at 1 month after axotomy. All studies with growth factors in axotomy models that have examined varied time points after axotomy found that the number of surviving neurons declined with time to varying degrees in spite of ongoing treatment [17,18]. The "slope" of this decline might give an indication of the relative potency of growth factors in this paradigm (e.g [18]). However, there was always a lasting effect observed if growth factors showed protection after shorter observation time

points. The purpose of our study was however not to compare relative efficacies of growth factors in this paradigm. We prefer to study questions of relative efficacy and effect stability in disease models closest and of relevance to the human indication targeted, which is ALS and SOD1-mutant mice in our case.

The observation that the G-CSF receptor was induced by axotomy parallels findings from other neurological disease models, such as stroke, spinal cord injury, or ALS [6,7], and underlines the notion that the G-CSF system is part of an endogenous protective system for neurons. This is certainly an argument for the use of G-CSF as a pharmacological agent that addresses an endogenously pre-specified mechanism. Indeed, G-CSF is currently under clinical investigation in ischemic stroke [19,20], and ALS [21-23].

We have undertaken this experiment to better dissect mechanisms responsible for the previously demonstrated beneficial function of G-CSF in the SOD1(G93A) mouse model for ALS. We have chosen the axotomy model to clearly answer the question whether G-CSF exerts a direct influence on motoneuron apoptosis *in vivo*. We have demonstrated potent anti-apoptotic properties of this "redefined" neurotrophic factor *in vitro* either in cortical neurons [6], or in motoneurons [7], and we favoured the anti-apoptotic hypothesis due to the strong effect on motoneuron survival *in vivo*. However, ALS is a multifaceted disease, with many factors involved in the pathophysiology [24-26], and the SOD1(G93A) models reproduce this complexity with discussed involvement of the neuromuscular junction, the immune system, glial cells and others. Moreover, G-CSF is a pleiotropic factor that for example also impacts on immunocompetence and inflammatory reactions. The data presented here clearly demonstrate a potent effect of G-CSF on motoneuron apoptosis *in vivo*, and support our assumption that anti-apoptosis plays a central role in the observed effects in the SOD1 transgenic ALS model.

Since G-CSF has such a potent protective role in apoptosis mediated by cell-inherent mechanisms as a response to nerve damage the interesting question arises whether the G-CSF system might also play a role in developmental death of motoneurons. This has indeed been shown for a number of neurotrophic factors that protect in the axotomy paradigm [27]. We do not believe that this is a confounding factor in our case since the expression of the CaMKII driven tTA is switched on during P2 and P5 [28-30], while the sensitive period for physiological motoneuron death is between E14 and P3 [27].

Although we do not see significant effects on the number of contralateral motoneurons in the different transgenic crosses, there is an interesting trend ($p = 0.1$) towards more motoneurons contralaterally in the G-CSF

overexpressors compared to littermates not transgenic for the CaMKII tta driver. One might speculate that a reason for this trend observation could be contralateral effects of axotomy that are counteracted by G-CSF. This slight nominal difference on the contralateral side does however not change our result, since the protective effect of G-CSF is also highly significant when regarding ipsi-/contralateral ratios instead of ipsilateral cell numbers.

The mechanisms responsible for counteraction of apoptosis elicited by G-CSF in neurons have been previously delineated by us: Activation of AKT in neurons and induction of stat3 and bcl-proteins [6]. The AKT and stat3 pathways play a crucial role for the survival of the axotomized motoneurons [31,32]. It is therefore highly likely that G-CSF mediates its protective effect via these pathways in the axotomy paradigm as well.

Conclusions

Here we have shown that G-CSF counteracts motoneuron death in a model of neonatal axotomy-induced apoptosis. This is most likely mediated by direct actions of the protein on motoneurons *in vivo*, and suggests that the protection offered by G-CSF in ALS mouse models is due to its direct neuroprotective activity. Moreover, our data strengthen the overall evidence that G-CSF is a candidate drug for the treatment of ALS.

Methods

Generation of G-CSF-overexpressing mice

Generation of the BEG transgenic lines is also described in [7]. We cloned the cDNA for murine G-CSF in a bi-directional Tet-transactivator (tta) responsive vector (pBI, Clontech). EYFP was inserted on the other side of the promoter for easy visualization of expression. To generate the pBI-EYFP-G-CSF ("pBEG") plasmid, G-CSF was amplified from a mouse brain cDNA library and inserted into the pBI Tet vector (Clontech) using the restriction sites NheI and EcoRV. EYFP was inserted into the multiple cloning site of the vector. Transgenic mice ("BEG") were generated, and selected for copy number integration. Copy numbers were estimated by quantitative PCR on genomic DNA by comparing pBEG/cyclophilin ratios of wild type and founder mice. For generating CNS-target G-CSF overexpressing mice, mice of line BEG6 were crossed with mice expressing the Tet-transactivator under control of the CaMKII-promoter (CaMKII-tta) [33], and successful activation of the construct was verified by EYFP imaging.

Sciatic nerve injury

Neonatal mice were anesthetized and immobilized by hypothermia after placement on ice, and unilateral sciatic nerve section was performed on postnatal day 5 (P5).

The skin of the right leg was incised parallel to the femur. To expose the sciatic nerve a longitudinal cut was made through the biceps femoris muscle with a sharpened forceps. The right sciatic nerve was transected at midhighlevel, a small piece (about 1-2 mm in length) of the nerve was removed to prevent reinnervation and the overlying skin of the thigh was sutured. Pups were warmed and returned to the mother. All animal manipulation followed current regulations of and were approved by the Regierungspräsidium Karlsruhe, Germany.

Immunohistochemistry

After deep anesthesia spinal cords were removed rapidly, immersed in 4% PFA, and embedded in paraffin. For immunofluorescence, microtome sections of paraffin-embedded tissues (10 μ m) were deparaffinated and microwaved (citrate buffer at 600 W for 15 min). For double-fluorescence staining, sections were incubated simultaneously with the G-CSF receptor antiserum (SC-694; Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:100) and the CHAT antibody (AB144P; Chemicon Europe Ltd., UK; 1:100) at 4°C overnight. After enhancing the G-CSF receptor staining by adding a biotinylated anti-rabbit secondary antibody (Dianova, Hamburg, Germany; 1:200), sections were incubated with a Streptavidin-coupled fluorophore (Invitrogen, Karlsruhe, Germany; 1:200) or the appropriate fluorescence-coupled secondary antibody (Dianova, Hamburg, Germany; 1:200). The nuclei were counterstained with Hoechst 33342 (Molecular Probes, 1:10000). Controls included omission of primary antibodies, fluorescence swapping and single-fluorescence stainings. Pictures were captured by video camera (Olympus DP71) coupled to a fluorescent microscope (Olympus IX80). To quantify staining intensity for the G-CSF receptor, pictures were analyzed with an image processing program (ImageJ). Intensity of grey levels were calculated for each motoneuron and normalized to its area.

For light-microscopic CHAT-staining coronal paraffin sections from the lumbar spinal cord (P9) were stained with the CHAT antibody using the avidin-biotin complex technique with DAB as chromogen (DakoCytomation), and counterstained with hemalaun.

Counting of motoneurons

Counting of motoneurons was performed at postnatal day 9 (P9), i.e. 4 days following axotomy at P5. Spinal cord paraffin sections of a thickness of 10 μ m, spaced by 100 μ m over a length of 0.5 mm, were counted at the spinal level L4-L5. Motor axons that constitute the sciatic nerve in C57/bl6 mice originate from L3 to L5 [34]. All neurons in the ventral horn were counted as α motoneurons if they had a clearly identifiable nucleolus,

were $>300 \mu\text{m}^2$ in size and were CHAT-positive. Counting was performed with pictures acquired with the LMD 6000 microscope (Leica) and its system program.

Quantitative reverse transcription polymerase chain reaction

RNA was isolated from spinal cords using RNeasy Mini kit (Qiagen). Complementary DNA was synthesized from 1 mg total RNA using oligo-dT primers and superscript III reverse transcriptase (Invitrogen), according to standard protocols. Quantitative reverse transcription-polymerase chain reaction (RT-PCR) was performed using the Lightcycler system (Roche) with SYBR-Green staining of double-stranded DNA. Cycling conditions were as follows: 10 min at 95°C; 5 s at 95°C, 10 s at the annealing temperature of 64°C, 30 s at 72°C for 50 cycles and 10 min at 95°C. The following primers were used: 'G-CSFR-2582s':TGT GCC CCA ACC TCC AAA CCA;'G-CSFR-2817as':GCT AGG GGC CAG AGA CAG AGA CAC. Product specificity was ensured by melting curve analysis and electrophoresis on agarose gel. Relative regulation levels were derived after normalization to cyclophilin: 'cyc5':ACC CCA CCG TGT TCT TCG AC;'acyc300':CAT TTG CCA TGG ACA AGA TG.

Statistics

Experiments were performed in a completely randomized and blinded manner. The experimenter was blinded to the genotype of the animals at the time of the experiment, and at the time of histological evaluation. For comparisons of 2 groups the ttest was employed. For 3 group comparisons, ANOVA was used, followed by post-hoc Fisher's test for contrasts. A p value < 0.05 was considered statistically significant. Statistical analyses were done using JMP 7.0.1 (SAS Institute).

Additional file 1: Description: Shown is the histogram distribution of CHAT-positive cells in L4/5 for the 3 different genotypes examined, and for the ipsi- and contralateral side.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2202-11-25-S1.pdf>]

Additional file 2: Description: Table of the motoneuron quantification data. Given are the absolute numbers and percentages of all CHAT positive cells; the mean size of all CHAT positive cells and the number of a motoneurons per section for the 3 genotypes examined (each for the ipsilateral and contralateral side).

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2202-11-25-S2.pdf>]

Acknowledgements

We thank Gisela Eisenhardt for expert technical assistance.

Author details

¹SYGNIS Bioscience, Im Neuenheimer Feld 515, 69120 Heidelberg, Germany.

²University of Strasbourg, Faculty of Medicine, UMRS692, Strasbourg, France.

³INSERM U692, Strasbourg, France.

Authors' contributions

CP, LD, AH and AS conceived and planned the experiments, AS performed statistical analyses, AH conducted all experiments. CP, LD, AH and AS wrote the manuscript. All authors read and approved the final manuscript.

Received: 25 June 2009 Accepted: 23 February 2010

Published: 23 February 2010

References

1. Welte K, Platzer E, Gabrilove JL, Lu L, Levi E, Polivka A, Mertelsmann R, Moore MA: Purification to apparent homogeneity and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. *Haematol Blood Transfus* 1985, **29**:398-401.
2. Frampton JE, Lee CR, Faulds D: Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia. *Drugs* 1994, **48**(5):731-760.
3. Lee ST, Chu K, Jung KH, Ko SY, Kim EH, Sinn DI, Lee YS, Lo EH, Kim M, Roh JK: Granulocyte colony-stimulating factor enhances angiogenesis after focal cerebral ischemia. *Brain Res* 2005, **1058**(1-2):120-128.
4. Kawada H, Takizawa S, Takanashi T, Morita Y, Fujita J, Fukuda K, Takagi S, Okano H, Ando K, Hotta T: Administration of hematopoietic cytokines in the subacute phase after cerebral infarction is effective for functional recovery facilitating proliferation of intrinsic neural stem/progenitor cells and transition of bone marrow-derived neuronal cells. *Circulation* 2006, **113**(5):701-710.
5. Hartung T: Anti-inflammatory effects of granulocyte colony-stimulating factor. *Curr Opin Hematol* 1998, **5**(3):221-225.
6. Schneider A, Kruger C, Steigleder T, Weber D, Pitzer C, Laage R, Aronowski J, Maurer MH, Gassler N, Mier W, et al: The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. *The Journal of clinical investigation* 2005, **115**(8):2083-2098.
7. Pitzer C, Kruger C, Plaas C, Kirsch F, Dittgen T, Muller R, Laage R, Kastner S, Suess S, Spoelgen R, et al: Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis. *Brain* 2008, **131**(Pt12):3335-3347.
8. Sun W, Oppenheim RW: Response of motoneurons to neonatal sciatic nerve axotomy in Bax-knockout mice. *Mol Cell Neurosci* 2003, **24**(4):875-886.
9. Dupuis L, Pehar M, Cassina P, Rene F, Castellanos R, Rouaux C, Gandelman M, Dimou L, Schwab ME, Loeffler JP, et al: Nogo receptor antagonizes p75NTR-dependent motor neuron death. *Proc Natl Acad Sci USA* 2008, **105**(2):740-745.
10. Farel PB: Naturally occurring cell death and differentiation of developing spinal motoneurons following axotomy. *J Neurosci* 1989, **9**(6):2103-2113.
11. Schmalbruch H: Loss of sensory neurons after sciatic nerve section in the rat. *The Anatomical record* 1987, **219**(3):323-329.
12. Sendtner M, Kreutzberg GW, Thoenen H: Ciliary neurotrophic factor prevents the degeneration of motor neurons after axotomy. *Nature* 1990, **345**(6274):440-441.
13. Yan Q, Elliott JL, Matheson C, Sun J, Zhang L, Mu X, Rex KL, Snider WD: Influences of neurotrophins on mammalian motoneurons in vivo. *Journal of neurobiology* 1993, **24**(12):1555-1577.
14. Vanderluit JL, McPhail LT, Fernandes KJ, McBride CB, Huguenot C, Roy S, Robertson GS, Nicholson DW, Tetzlaff W: Caspase-3 is activated following axotomy of neonatal facial motoneurons and caspase-3 gene deletion delays axotomy-induced cell death in rodents. *Eur J Neurosci* 2000, **12**(10):3469-3480.
15. Imaizumi K, Benito A, Kiryu-Seo S, Gonzalez V, Inohara N, Lieberman AP, Kiyama H, Nunez G: Critical role for DP5/Harakiri, a Bcl-2 homology domain 3-only Bcl-2 family member, in axotomy-induced neuronal cell death. *J Neurosci* 2004, **24**(15):3721-3725.
16. Perrelet D, Ferri A, MacKenzie AE, Smith GM, Korneluk RG, Liston P, Sagot Y, Terrado J, Monnier D, Kato AC: IAP family proteins delay motoneuron cell death in vivo. *Eur J Neurosci* 2000, **12**(6):2059-2067.

17. Baumgartner BJ, Shine HD: **Neuroprotection of spinal motoneurons following targeted transduction with an adenoviral vector carrying the gene for glial cell line-derived neurotrophic factor.** *Exp Neurol* 1998, **153**(1):102-112.
18. Matheson CR, Wang J, Collins FD, Yan Q: **Long-term survival effects of GDNF on neonatal rat facial motoneurons after axotomy.** *Neuroreport* 1997, **8**(7):1739-1742.
19. Schabitz WR, Schneider A: **Developing granulocyte-colony stimulating factor for the treatment of stroke: current status of clinical trials.** *Stroke* 2006, **37**(7):1654, author reply 1655..
20. Schabitz WR, Schneider A: **New targets for established proteins: exploring G-CSF for the treatment of stroke.** *Trends Pharmacol Sci* 2007, **28**(4):157-161.
21. Nefussy B, Artamonov I, Deutsch V, Naporstek E, Nagler A, Drory VE: **Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: A pilot study.** *Amyotroph Lateral Scler* 2009, 1-7.
22. Tarella C, Rutella S, Gualandi F, Melazzini M, Scime R, Petrini M, Moglia C, Ulla M, Omede P, Bella VL, *et al*: **Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyte-colony-stimulating factor in patients with amyotrophic lateral sclerosis: results from a multicenter prospective trial.** *Cytotherapy* 2009, **12**(1):50-59.
23. Zhang Y, Wang L, Fu Y, Song H, Zhao H, Deng M, Zhang J, Fan D: **Preliminary investigation of effect of granulocyte colony stimulating factor on amyotrophic lateral sclerosis.** *Amyotroph Lateral Scler* 2008, 1-2.
24. Blackburn D, Sargsyan S, Monk PN, Shaw PJ: **Astrocyte function and role in motor neuron disease: a future therapeutic target?.** *Glia* 2009, **57**(12):1251-1264.
25. Xiao Q, Zhao W, Beers DR, Yen AA, Xie W, Henkel JS, Appel SH: **Mutant SOD1(G93A) microglia are more neurotoxic relative to wild-type microglia.** *J Neurochem* 2007, **102**(6):2008-2019.
26. Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, Khan J, Polak MA, Glass JD: **Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man.** *Exp Neurol* 2004, **185**(2):232-240.
27. Sendtner M, Pei G, Beck M, Schweizer U, Wiese S: **Developmental motoneuron cell death and neurotrophic factors.** *Cell Tissue Res* 2000, **301**(1):71-84.
28. Bayer KU, Lohler J, Schulman H, Harbers K: **Developmental expression of the CaMKinase I isoforms: ubiquitous gamma- and delta-CaM kinase II are the early isoforms and most abundant in the developing nervous system.** *Brain Res Mol Brain Res* 1999, **70**(1):147-154.
29. Petralia RS, Sans N, Wang YX, Wenthold RJ: **Ontogeny of postsynaptic density proteins at glutamatergic synapses.** *Mol Cell Neurosci* 2005, **29**(3):436-452.
30. Gross C, Zhuang X, Stark K, Ramboz S, Oosting R, Kirby L, Santarelli L, Beck S, Hen R: **Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult.** *Nature* 2002, **416**(6879):396-400.
31. Namikawa K, Honma M, Abe K, Takeda M, Mansur K, Obata T, Miwa A, Okado H, Kiyama H: **Akt/protein kinase B prevents injury-induced motoneuron death and accelerates axonal regeneration.** *J Neurosci* 2000, **20**(8):2875-2886.
32. Schweizer U, Gunnarsen J, Karch C, Wiese S, Holtmann B, Takeda K, Akira S, Sendtner M: **Conditional gene ablation of Stat3 reveals differential signaling requirements for survival of motoneurons during development and after nerve injury in the adult.** *J Cell Biol* 2002, **156**(2):287-297.
33. Mansuy IM, Winder DG, Moallem TM, Osman M, Mayford M, Hawkins RD, Kandel ER: **Inducible and reversible gene expression with the rtTA system for the study of memory.** *Neuron* 1998, **21**(2):257-265.
34. Rigaud M, Gemes G, Barabas ME, Chernoff DI, Abram SE, Stucky CL, Hogan QH: **Species and strain differences in rodent sciatic nerve anatomy: implications for studies of neuropathic pain.** *Pain* 2008, **136**(1-2):188-201.

doi:10.1186/1471-2202-11-25

Cite this article as: Henriques *et al*: G-CSF protects motoneurons against axotomy-induced apoptotic death in neonatal mice. *BMC Neuroscience* 2010 **11**:25.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

